Roche cancer drug gets China nod

Aug 20, 2018

Roche Holding has announced that its cancer drug, Alecensa, has been granted marketing authorization in China — a beneficiary of China’s recent efforts to speed up approvals.

China’s National Drug Administration backed the Swiss drugmaker’s Alecensa to treat an aggressive kind of lung cancer, called anaplastic lymphoma kinase-, or ALK-positive, less than a year after European and U.S. approvals. The approval comes after authorizations in over 57 countries as a first-line treatment.

China has only recently opted to accept overseas trial data to accelerate approvals after high costs and a lack of access to new treatments have forced patients to turn to a growing counterfeit drug market.

Read the press release

Want to get news like this in your inbox?  Subscribe to our eNewsletter here!

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments